E-mail: info@pharmintel.co.in
Contact: +91-9643310025, 9643312749
Generic selectors
Exact matches only
Exact matches only
Search in title
Search in title
Search in content
Search in content
Search in excerpt
Search in posts
Search in posts
Search in pages
Search in pages
Filter by Categories
Annual brand plans
Annual brand plans
Autoimmune diseases
Autoimmune diseases
Blog
Blog
Conference support
Conference support
Corporate strategy and R amp D consulting
Corporate strategy and R & D consulting
KOL support
KOL support
Medical
Medical
MSL training
MSL training
Orphan Diseases
Orphan Diseases
Pre amp post launch activities
Pre-& post launch activities
Sales amp marketing
Sales & marketing
Sales force training
Sales force training
Home
About
Services
Find a report
Orphan Diseases
Autoimmune Diseases
Media
Blog
Press Release
Artificial Intelligence
Prescription Audit
NEWS Analytics
Contact Us
Career
Tagrisso (Osimertinib)- AstraZeneca’s non-small cell lung cancer drug backed off by The National Institute of Health and Care Excellence (NICE)
Posted on
January 26, 2020
by
pharmintel
—
No Comments ↓
Home
›
Archive for Blog
›
Page 4
Blog Archives
[wpb_category_accordion taxonomy="category" orderby="name" order="ASC" show_count="no" hide_empty="yes" icon="+"]
Tagrisso (Osimertinib)- AstraZeneca’s non-small cell lung cancer drug backed off by The National Institute of Health and Care Excellence (NICE)
Wait over!! Alzheimer’s treatment is on the way…
A New Hope for Multiple Myeloma Patients – REGN5458 (BCMAXCD3)
Unmet Medical Need Analysis in sickle cell disease: Approval of OXBRYTA (voxelotor)
Unmet Medical Need Analysis of vaso-occlusive crisis in sickle cell disease: Approval of Adakveo (crizanlizumab-tmca)
Posts navigation
Previous page
Page
1
…
Page
3
Page
4
Page
5
…
Page
7
Next page
If you have any query for account and more... We are available
Contact
+91 9643310025, 9643312749
Email
info@pharmintel.co.in
© 2024
Pharmintel
Powered by
Creative Brain Web